
## Patrick J Grohar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2908124/publications.pdf Version: 2024-02-01



DATRICK | CROHAR

#	Article	IF	CITATIONS
1	Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening. Journal of the National Cancer Institute, 2011, 103, 962-978.	6.3	174
2	Ecteinascidin 743 Interferes with the Activity of EWS-FL11 in Ewing Sarcoma Cells. Neoplasia, 2011, 13, 145-IN10.	5.3	103
3	Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth. Clinical Cancer Research, 2014, 20, 1190-1203.	7.0	64
4	Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Cancer Research, 2016, 76, 6657-6668.	0.9	57
5	Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clinical Cancer Research, 2016, 22, 4105-4118.	7.0	56
6	A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript. Cancer Chemotherapy and Pharmacology, 2017, 80, 645-652.	2.3	54
7	Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma. Cell Reports, 2016, 14, 598-610.	6.4	53
8	Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner. Clinical Cancer Research, 2019, 25, 3417-3429.	7.0	32
9	Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. Sarcoma, 2020, 2020, 1-9.	1.3	12
10	One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma. Journal of Bone Oncology, 2021, 31, 100404.	2.4	12
11	18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FL1 Activity and Ewing Sarcoma. Scientific Reports, 2016, 6, 33926.	3.3	10
12	Lurbinectedin Inhibits the EWS–WT1 Transcription Factor in Desmoplastic Small Round Cell Tumor. Molecular Cancer Therapeutics, 2022, 21, 1296-1305.	4.1	8
13	Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatric Blood and Cancer, 2021, 68, e29188.	1.5	7
14	Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor. EMBO Molecular Medicine, 2021, 13, e12640.	6.9	7
15	Ewing sarcoma and related <scp>FET</scp> family translocationâ€associated round cell tumors: A century of clinical and scientific progress. Genes Chromosomes and Cancer, 2022, 61, 509-517.	2.8	5
16	Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy: A long-term follow-up report from Children's Oncology Group study AEWS0031 Journal of Clinical Oncology, 2022, 40, 11505-11505.	1.6	2
17	A report on the review of archived osteosarcoma and EWING sarcoma specimens at the Biopathology Center, BONE Sarcoma Committee, Children's Oncology Group Journal of Clinical Oncology, 2022, 40, 11524-11524.	1.6	1